In addition, some of these tumors may be responsive to drugs that are already approved for the treatment of sarcomas like Pazopanib (Votrient®), which is a multi-kinase VEGF based inhibitor that has activity against the PDGFR pathway as well. This evidence concerns the gene PDGFRB and sarcoma.